Introduction and Aims: Alveolar haemorrhage (AH) is a potential lifethreatening feature of ANCA associated vasculitis (AAV): previous studies report a 50% mortality in severe presentations and AH was found to increase the risk of death in microscopic polyangiitis ninefold. AH results from a pauci-immune alveolar capillaritis. Aims: To characterise the prevalence and outcomes (end-stage renal failure and mortality) of AH further. We undertook a retrospective analysis of AH in 387 patients with AAV from 3 RCTs of the European Vasculitis Study Group (EUVAS): NORAM (non-renal vasculitis), CYCAZAREM (major organ involvement but creatinine < 500 mmol/l) and MEPEX (severe renal disease, creatinine >500 micromol/l). Methods: Retrospective patient data was retrieved from the EUVAS database which was analysed using SPSS and Access. AH was defined at diagnosis by haemoptysis and/or pulmonary infiltrates scored by BVAS (Birmingham Vasculitis Activity Score). Severe, ventilator dependent, AH was an exclusion criterion for NORAM and MEPEX. Results: 93/387 (24%) AAV patients had AH at presentation. Haemoptysis, present in 16.3%, was severe in 10 patients; the remainder had pulmonary infiltrates without haemoptysis. AH developed later, after the initial presentation, in 16 other patients: 5 within the first 6 weeks and 5 after the first year. Renal involvement accompanied 78/93 (83.9%) of those presenting with AH and 160/294 (54.4%) of those without AH (p=0.0001). Mean presenting creatinine in those with and without AH was 385 micromol/l and 387 micromol/l respectively (p>0.005, ns). AH was present in 40 out of 137 (29.2%) with severe renal disease (creatinine > 500 micromol/l) and in 69/250 (27.6%) of those without severe renal disease (p=0.81). Of 161 with PR3-ANCA, 52 (32.3%) had AH vs 41/131 with MPO-ANCA and AH (31.3%) (p=0.9, ns); 4/22 (18.2%) ANCA negative patients had AH (p=0.6, ns). 19/93 (20.4%) patients presenting with AH developed ESRF vs 49/294 (16.7%) who did not present with AH (p=0.44). All-time mortality was 32.3% (30/93) in those with AH and 25.9% (76/294) in those without AH (p=0.23). 14/30 (46.7%) AH patients died within the first year vs 32/76 (42.1%) without AH (p=0.67, ns). All 14/14 of the AH patients who died in the first year had severe renal disease at presentation (creatinine > 500 micromol/l). 23 MEPEX patients with AH received high dose IV methylprednisolone and 17 plasma exchange. 12 of the 24 (50%) MEPEX AH patients who died were treated with plasma exchange and 12 with methylprednisolone. Causes of death were sepsis in16/30 (53.3%) and respiratory failure in 8/30 (26.7%). Conclusions: Alveolar haemorrhage was present in 24% of AAV patients at presentation and subsequently developed in a further 4%. The frequency of AH was not influenced by ANCA subtype. AH was associated with the presence but not the severity of renal vasculitis, consistent with the two manifestations having a common pathogenesis. In contrast to previous reports, AH was not associated with a higher mortality, which may be a reflection of the exclusion of those with severe AH.
(glomerulosclerosis index, GSI), immunohistochemistry (fibronectin, TGF-β 1 ,desmin) and mRNA expression analysis (TGF-β 1 , eNOS, nNOS, all normalized to GAPDH). Results: cGMP levels were restored due to vardenafil treatment (Co: 14±9; STZ: 8±1; STZ-vard: 26±15 pmol/mL, p=0.009). Diabetes lead to severe proteinuria (PC: Co: 3.6±0.9; STZ: 22.5±9.2; STZ-vard: 11.2±4.9, p=0.0001), significant glomerulosclerosis (GSI: Co: 1.0±0.1; STZ: 2.1±0.1; STZ-vard: 1.3±0.3, p=0.002), markedly increased TGF-β 1 immunostaining (score: Co: 0.1±0.1; STZ: 2.1±0.3; STZ-vard: 1.2±0.3, p=0.0012) and fibronectin immunostaining (score: Co: 0.12±0.12; STZ: 1.15±0.13; STZvard: 0.82±0.14, p=0.002). The extent of proteinuria, glomerulosclerosis, TGF-β 1 and fibronectin staining was significantly decreased in treated rats, accompanied by lower TGF-β 1 mRNA expression levels (TGF-β 1 expression: Co: 0.7±0.1; STZ: 1.1±0.1; STZ-vard: 0.6±0.1, p=0.004) compared to STZ-Co group. Vardenafil treatment decreased desmin expression of podocytes (score: Co: 0.08±0.03; STZ: 0.49±0.13; STZ-vard: 0.31±0.08, p=0.002). Altough mRNA expression level of eNOS was similar in all groups, nNOS mRNA expression was significantly higher in diabetic rats and was not influenced by vardenafil treatment (nNOS expression: Co: 0.22±0.14; STZ: 1.08±0.32; STZ-vard: 1.16±0.33, p=0.008). Conclusions: Restoring cGMP levels with selective PDE5 inhibitor vardenafil effectively attenuated podocyte damage and glomerulosclerosis in diabetic rats. We conclude that increased renal PDE5 activity in diabetes may play an important role on podocyte damage and progression of nephropathy.
Introduction and Aims:
Both classical PKC isoforms, PKC-α and -β, have been implicated in the pathogenesis of diabetic microvascular diseases. We previously elucidated the specific role of these individual isoforms and revealed that activation of the PKC-β-isoform contributes to high-glucoseinduced renal fibrosis whereas perlecan as well as nephrin and VEGF expression are regulated by a PKC-α-isoform-dependent signaling pathway leading to diabetic albuminuria. Methods: We now tested the hypothesis if deletion of both classical PKC isoforms is able to completely abolish the development of diabetic nephropathy in the streptozotocin-induced diabetic mouse model. We therefore studied distinct pharmacological approaches while inhibiting both classical PKC isoforms and validated the phenotype of nondiabetic and streptozotocin-induced diabetic homozygeous PKC-α/β double knock-out mice (PKC-α/β -/-) compared to appropriate 129/SV wild type mice. Results: After 8 weeks of diabetes mellitus the high-glucose-induced renal and glomerular hypertrophy as well as the increased expression of extracellular matrix proteins such as collagen and fibronectin was abolished in the PKC-α/β -/-mice compared to WT controls. Furthermore, the high-glucose-induced expression of the profibrotic cytokine TGF-β1 was significantly diminished in the PKC-α/β -/-mice in comparison to diabetic WT mice. The loss of the basal membrane proteoglycan perlecan and the podocyte protein nephrin is prevented in the diabetic state in the PKC-α/β -/-mice. Furthermore, we were able to demonstrate, that a PKC-α/β inhibitor had a similar effect. Conclusions: In summary, blockade of the two prominent PKC isoforms α and β are able to prevent early diabetic nephropathy while inhibiting prosclerotic glomerular and tubulo-interstitial changes as well as the development of albuminuria. These results demonstrate that downregulation of the dual PKC-isoform activation in the diabetic state in vivo is a suitable therapeutic target in the prevention of diabetic microvascular complications such as diabetic nephropathy.
OSu008 REGULATION OF TRPC6 CHANNELS IN PODOCYTES BY VEGF
Florian Thilo, Ying Liu, Martin Tepel. Charite CBF, Nephrology, Berlin, Germany Introduction and Aims: Increased plasma concentrations of vascular endothelial growth factor (VEGF) and increased expression of transient receptor potential canonical type 6 (TRPC6) channels in podocytes have been associated with kidney diseases. Now, we investigated whether VEGF regulates TRPC6 in podocytes. Methods: The expression of TRPC6-mRNA and TRPC6 protein were analyzed in cultured podocytes after administration of VEGF165 using quantitative real-time RT-PCR and immunoblotting. Processing of YFPtagged TRPC6 in podocytes was analyzed using confocal laser scanning microscopy. TRPC6-associated calcium influx was measured fluorometrically. Results: Administration of 10ng/mL VEGF165 to podocytes significantly increased TRPC6-mRNA by 3.03fold and TRPC6 protein by 6.72fold (n=10; p<0.01). The effects of VEGF165 were dose-dependent and could be blocked by phosphoinositide-3-kinase inhibitors. VEGF165 increased YFP-tagged-TRPC6 protein processing in podocytes. VEGF165 significantly increased calcium influx in podocytes which was induced by the TPRC6 specific agonist hyperforin. The hyperforin-induced calcium influx was significantly lower in podocytes after gene knockdown using siRNA against TRPC6. Calcineurin activity and podocyte migration were significantly enhanced after administration of VEGF165. We observed a significant association between VEGF receptor type 2 (VEGFR-2)-mRNA with TRPC6-mRNA (n=48; r 2 =0.585; p<0.0001) in human renal cortex. Conclusions: It is concluded that VEGF regulates TRPC6 processing in podocytes via a phosphoinositide-3-kinase dependent pathway.
OSu009 HYPERLIPIDEMIA AGGRAVATED DIABETES MELLITUS ASSOCIATED RENAL DISEASE IS BLOCKED BY LXR NUCLEAR RECEPTORS
Introduction and Aims: Abnormal lipid metabolism and renal accumulation of lipids are pathogenetic factors in diabetic nephropathy. Liver X receptors (LXRa,b) , members of the nuclear receptor superfamily are activated by oxidized cholesterols. Forming heterodimers with RXR they regulate genes linked to lipid and carbohydrate homeostasis and inhibit inflammatory gene expression in macrophages. In the present study the effects of LXR activation were analyzed on diabetes and/or hyperlipidemia induced renal damage and assigned to one LXR isoform. Methods: Diabetes was induced by administration of streptozotozin in WT and LDLR-deficient (LDLR-/-) mice on standard chow or western diet with or without the nonselective synthetic LXR-agonist, GW3965 (GW) (20 mg/kg/day). In addition, to gain insight into macrophage-LXRa mediated effects hyperglycemic/ hyperlipidemic mice with macrophage overexpression of LXRa were evaluated after 20 weeks. Results: LDLR-/-mice on Western diet and diabetic WT mice had increased glomerular cellularity and mesangial matrix. LDLR-/-mice on Western diet also showed occasional glomerular and tubulointerstitial foam cells accompanied by a tubulointerstitial mononuclear cell infiltrate. Glomerular foam cell formation was significantly increased when diabetes was induced in the hyperlipidemic mice and reduced by LXR activation. LXR significantly reduced hyperglycemia induced mesangial matrix increase in glomeruli (e.g. 27.2±0.6 vs 19.9±0.2; diabetes vs diabetes+GW; p<0.01) and led to preserved renal function in hyperlipidemic, diabetic mice (e.g. serum creatinine: 0.39±0.2 vs 0.06± 0.01 mg/dl, diabetic-hyperlipidemic vs diabetichyperlipidemic+GW; p<0.01). The number of F4/80+ macrophages was reduced in the interstitium of hyperglycemic and/or hyperlipidemic kidneys with LXR activation. Macrophage specific overexpression of LXRa was sufficient to significantly ameliorate hyperglycemia and/or hyperlipidemia induced renal damage and proteinuria (proteinuria: 4.7±1.0 vs 1.2±0.3 mg/ml, LDLR-/-diabetic vs LDLR-/-diabetic + macrophage overexpression of LXRa; p<0.01). Conclusions: LXRa activity in macrophages was able to attenuate diabetic and hyperlipidemic renal lesions attesting the potent regulatory role of these non-steroidal nuclear receptors in metabolic diseases. The data also prove that monocytes/macrophages are main mediators of diabetic renal lesions. More recently we have shown that curcumin prevented hyperfiltration and decreased albumin excretion rates in early DN in association with decreased renal VEGF expression. It is currently unknown if the curcumin effects are additive to angiotensin blockade, which is an established approach to maintain renal function in early DN. Methods: To examine this question, we treated ZSF rats, maintained on a high calorie diet, with either plain water (control) or curcumin (1mg/ml) or losartan (25mg/L) and losartan +curcumin) in drinking water from week 8th to 12th week of age. The losartan dose was chosen Body weights and urine protein rates were measured every week. Renal function, (endogenous creatinine clearance) daily urinary protein excretion rates, and urinary VEGF levels were examined at the beggining and end of the study. Results: Both curcumin and losartan were well tolerated as evidenced by increases in body weights and fluid consumption records. The daily urinary protein excretion decreased with losartan and curcumin compared to control group and was lower with the combined treatment than either alone. Both curcumin and losartan obliterated the hyperfiltration phase and there was no additional benefit of both together. Urinary VEGF levels were lowered with the combined therapy than with either losartan or curcumin alone. 
OSu010 DIFERULOYLMETHANE (CURCUMIN) POTENTIATES SALUTORY EFFECTS OF ANGIOTENSIN BLOCKADE IN EARLY DIABETIC KIDNEY

Conclusions:
We conclude that curcumin decreased urinary protein excretion rates and VEGF levels in diabetic ZSF rats with early nephropathy and these effects were augmented when curcumin was co-adminstered with an angiotensin receptor blocker. The findings suggest that the reno-protective mechanisms of curcumin are additive to angiotensin blockade and may involve pathways that may overlap with losartan but not entirely similar.
Haemodialysis
OSu011 RELATIONSHIP BETWEEN CENTRAL AND REGIONAL Introduction and Aims: Understanding fluid dynamics during hemodialysis (HD) is important for the management of hydration in HD patients. Fluid is removed from the blood volume compartment by ultrafiltration (UF) and refilling from the interstitial compartment shift to blood compartment to compensate for the reduction. We hypothesize that change of fluid volume in the calf can represent the removal of total excess fluid volume in the body and excess fluid in the calf is the last volume to be removed during HD with UF. The aim of this study was to investigate relationships of change in the calf resistivity to changes in the chest bioimpedance, relative blood volume and blood pressure during HD and UF. Methods: 54 HD patients (25f/28m, age 62.5±16 year, height 166±12 cm, post-HD weight 71±18 kg) were studied during HD treatment. Blood volume monitor (BVM, Fresenius, AG, Germany), blood pressure monitor (BPM, Fresenius, AG, Germany), ZOE fluid monitor (Noninvasive Medical Technologies, Las Vegas) and calf bioimpedance spectroscopy (cBIS, Xitron Technologies, San Diego, CA) were used to continuously measure relative change in blood volume (RBV, %), blood pressure (SBP, mmHg), chest electrical impedance (Zo, Ohm) and the calf extracellular resistance (Re, Ohm) and calf resistivity (ρ N Ohm.m 3 /kg) in every 10 minutes, respectively. The curve of relative change in Re (Re0/Ret) and in Zo (Zo0/Zot) represent removal of fluid volume from the calf and chest respectively. The correlations between the measurements were analyzed for all patients. Results: Fig. 1 shows the curves of continuous measurement for all patients with ZOE (Zo0/Zot) and cBIS (Re0/Ret) during treatment. The decrease in ZOE was less than 5% but decrease in cBIS more than 20% from the beginning of treatment. Fig.2 and Fig.3 indicate the correlations (r 2 ) of calf resistivity and Zo (r 2 = 0.88) and RBV (r 2 = 0.93), during treatment in all patients. These results demonstrate that either the fluid removed from the trunk or from the blood volume can be reflected in change in calf resistivity. Fig.4 shows the decrease in systolic blood pressure (SBP) associated with increase in calf resistivity (r 2 =0.57, P<0.05). A nonlinear relationship between ZOE and the calf resistivity ( Fig. 2) suggests that the calf contains relative more fluid than in the chest toward the end of the treatment.
FLUID DYNAMICS DURING HEMODIALYSIS USING SEGMENTAL BIOIMPEDANCE AND BLOOD VOLUME MONITORING
Conclusions:
Results provide clear evidence that changes in calf resistivity proportionally represent the total body fluid removed by HD and UF. Since the calf is more hydrated than other segments of the body, the excess body fluid can be considered to be completely removed when the fluid volume in the calf is normal.
Introduction and Aims:
Thrice-weekly nocturnal hemodialysis (NHD) is a convenient way to extend treatment time on dialysis for both the patient and the dialysis center but there are few data on outcomes. We compared patients on NHD with matched controls on conventional hemodialysis (CHD) for mortality, hospitalization and treatment-related parameters. Methods: NHD was defined as starting after 5pm and lasting > 7h. Controls were drawn from patients who were prevalent on 1/1/2006 and matched for age, gender and diabetic status. Lab values and treatment parameters were collected as part of the ongoing quality-of-care initiative QiN ("Quality in Nephrology") of KfH. Primary outcomes were death and hospitalization. Secondary outcomes were treatment-related parameters. All patients were invited to participate in a yearly Quality of Life (QoL) assessment using the KDQOL questionnaire. Cox models were used to compare outcomes. All calculations were done with the "R" statistics environment. A two-sided p<0,05 was considered significant. Results: There were 494 patients and matched controls. Follow-up lasted from 1/2006 until 9/2009. The average age was 49,9 (±13,68) years, 25,1% were female and 15,2% were diabetic. Fewer cerebro-vascular events (10,14 vs. 18,37%; p<0,05) were recorded as comorbidities in the NHD group. Other comorbidities were similar. Time on dialysis at the start of observation (dialysis burden) was longer in NHD than in CHD (8,3 vs 5,9 y; p<0,05). Initial post-dialysis weight was higher in NHD (77,0 vs. 73,7 kg). Initial Albumin was 42,33 g/L vs. 40,55 g/L, and TSAT was 25,26% vs. 28,85% (all p<0,001) in NHD and the CHD group, respectively. Consistent with longer treatment times, eKt/V was significantly higher in NHD than in CHD (1,69 vs. 1,31; p<0,0001). All other parameters were similar.Risk of death, taking comorbidities, dialysis burden and initial weight into account, was substantially lower in NHD than in CHD (HR of death 0,75; p<0,05, 31 vs. 66/1000 life years; p<0,0001). There was no difference in normalized hospitalization days or days until first hospitalization. Approximately 35% of patients returned QoL surveys. There was no significant difference in the mental or physical summary scores, respectively, between the two modalities. Treatment-related parameters were stable during the 45 month observation period but phosphate and blood pressure decreased significantly in both groups. (Phosphate: from 1,86 to 1,71 mmol/L in NHD and from 1,91 to 1,81 mmol/L in CHD; BP: from 134/77 to 131/73 mmHg in NHD and 134/77 to 131/74 in CHD; all p<0,05). Conclusions: NHD was associated with a substantially lower risk of death in this multi-center prevalent cohort, when compared to controls matched for age, gender and diabetes. Quality of life was similar in both modalities. Most treatment-related parameters remained stable for the 45 month observation period. These results together with previous reports lend support to a prospective study of the benefits of thrice-weekly NHD. (Fig. 1) .
OSu013 HEMODIAFILTRATION (HDF): PATTERNS OF USE AND ASSOCIATION WITH OUTCOMES IN THE DIALYSIS OUTCOMES AND PRACTICE PATTERNS STUDY (DOPPS)
Conclusions: This novel hybrid model including AP markedly improves the prediction of end-HD systemic iCa compared to the previously described RCA model, with reduced average error and less scatter in the prediction. The prediction for systemic iCa at the end of HD (i.e., after on average 4 hours of dialysis treatment) was within about ±0.1 mmol/L of the actually measured iCa for most patients. Of note, the 4 outliers represent underestimations of systemic iCa, i.e., the model erred on the safe side. One of these patients maintained an unchanged systemic iCa while the other three showed an unexpected rise in iCa, possibly related to intradialytic calcium absorption from the gut or overshooting hormonal counter-regulation. 
Introduction and Aims:
The epidemic of cardiovascular disease in CKD is explained in part by traditional cardiovascular risk factors, by the uremia specific factors but also by the abnormalities of the mineral metabolism and the novel molecules involved in its regulation and in the vascular calcification process. Methods: In a population of 177 patients with CKD 2 and 3 we evaluated the link between the mineral metabolism abnormalities (Ca, P, CaxP), the regulatory factors (PTH, vitamin D, FGF 23 and fetuin A) and the severity of CAD assessed by coronarography in three subgroups defined by tertiles of CAD Gensini lesion severity score.
Results:
The mean serum values for FGF 23 was 28.1±17.3 ru/ml (median 21.9 ru/ml) and for fetuin A were 473.1±156. After the adjustments for traditional and uremia related cardiovascular risk factors, the FGF 23 (B=0.616; p=0.000) and fetuin A (B= -0.186; p=0.002) remained statistically significant predictors of the Gensini score, the model explaining 67% of the variation in the Gensini score (p=0.012).
Conclusions:
Our study suggests that in a relatively young population with mild to moderate CKD, and with less traditional cardiovascular risk factors, abnormal serum levels of FGF 23 and fetuin A appear early in the course of disease, and are independent major predictors for the coronary artery disease extent.
Introduction and Aims:
Oxidative Stress and Inflammation have been recognized as independent risk factors for mortality as well as for cardiovascular disease (CVD) in hemodialysis patients. Hemodialysis treatment itself is associated with accelerated oxidative stress, inflammation and atherosclerosis. The choice of the dialysis membrane is thought to be a central component in raising inflammatory markers. We hypothesized that high-flux dialysis (HF-HD) would be superior to low-flux dialysis (LF-HD) in respect to inflammatory status and oxidative stress. Methods: 221 darbepoetin-alfa treated maintenance hemodialysis patients (mean age 66 years, 55% male) from 14 centers were enrolled into a 20 week baseline period of LF-HD with a synthetic dialysis membrane. Thereafter, patients were randomly assigned to receive either a synthetic high-flux membrane or to continue on LF-HD for 52 weeks. Blood samples for measurements of myeloperoxidase (MPO), oxidized LDL (oxLDL) and the malnutrition inflammation score (MIS/anthropometry, albumin, BMI), highsensitive C-reactive protein (hsCRP) and hemoglobin (Hb) were collected before dialysis at the end of the baseline period and after 52 weeks. Results: 138 patients (67 for low-flux and 71 for high-flux) completed the trial according to the protocol. Wilcoxon's test for independent samples did not demonstrate a difference between LF-HD and HF-HD for the levels of MPO (mean ± SD: 47±69 vs 37±42 ng/ml), oxLDL (mean±SD: 374±233 vs 406±385 ug/ml), hsCRP (median: 5.4 vs 5.0 mg/l) or in the MIS score (mean ± SD: 11.0±3.2 vs 10.7±2.9; albumin 3.9±0.4 vs 4.0±0.5 g/dl) after 52 weeks of treatment. There was no difference in the hemoglobin levels between the two dialysis membranes (mean ± SD: 11.7±0.9 vs 11.7±1.2 g/dl) at the end of observation period. Dose of darbepoetin-alfa and iron administration were not different between the groups. Conclusions: Randomization to HF-HD or LF-HD did not result in differences in inflammation, oxidative stress or any changes in hemoglobin levels. Since inflammation and oxidative stress are key players in the accelerated vascular disease of dialysis patients, our data may help to explain the previously observed lack of benefit on mortality with high-flux dialyzer membranes, but do not reflect the outcome of patients in the MPO Study. Disclosure: This abstract was supported by Amgen. Introduction and Aims: Wasting is common in patients with end-stage renal disease, and often accompanied by inflammation and cardiovascular disease. The cardiovascular risk profile meaningfully changes in advanced chronic kidney disease, and little is known about the impact of wasting on specific clinical outcomes. This study examined the effects of wasting on the various components of cardiovascular outcome, and death due to infection. Methods: We analyzed data from 1255 hemodialysis patients with type 2 diabetes mellitus, participating in the German Diabetes and Dialysis Study (4D Study). Patients were categorized according to the presence or absence of wasting, defined by both a BMI ≤23 kg/m 2 and albumin level ≤3.8g/dl. By Cox regression analyses, the association of wasting with sudden cardiac death (n=160), myocardial infarction (n=200), combined cardiovascular events (n=469), and death due to infection (n=128) was investigated during 4 years of follow-up. Results: Compared to the patients without wasting (n=1147), patients with wasting (n=108) had a 3 fold increased risk of sudden cardiac death (HR 3.0, 95% CI 2.0-4.5), which hardly attenuated after multivariable adjustment (HR 2.5, 95% CI 1.6-3.8). There were trends for increased risks of stroke and deaths due to infection (HR adj 1.6 (0.8-3.2) and 1.5 (0.8-2.6), respectively), while myocardial infarction was not affected. The increased risk of combined cardiovascular events by 60% (HR adj 1.6 (1.2-2.1)) was mainly explained by the effect of wasting on sudden cardiac death, since no association was seen for combined cardiovascular events except sudden death.
OSu018 SUDDEN CARDIAC DEATH DUE TO WASTING IN DIABETIC HEMODIALYSIS PATIENTS
Conclusions:
The presence of wasting was strongly associated with sudden cardiac death, but not with myocardial infarction in diabetic hemodialysis patients. Non-atherosclerotic cardiovascular disease potentially plays a major role to account for the increased cardiovascular events in patients with wasting, suggesting the need for novel treatment strategies.
Introduction and Aims:
Size predictors (SP) such as Body Surface Area ((BSA), Lean Body Mass (LBM) and Volume (V) are frequently used in HD pts as adequacy treatment tools as well as outcome predictors.However, changes in body composition (BC) related to malnutrition and obesity are common in this population. The aim of this study was to analyze influence of changes in BC on SP. We used a recently validated device (BCM Fresenius) which distinguishes BC in terms of lean tissue mass (LTM), fat tissue mass (FTM) and total body water (TBW). Methods: We studied 1031 prevalent pts (age (years): 58±15; mean time on HD (TD): 5,6±5 years; women: 41%; diabetics: 17%) from 10 Units of Buenos Aires BC measurements were assessed with a portable whole body BIS (bioimpedance spectroscopy) device (BCM ® ).BCM provides information about TBW equivalent to the urea distribution volume (V) and nutritional status expresssed as LTI (Lean Tissue Index=LTM/height 2 ), FTI (Fat Tissue Index = FTM/height 2 ) and BMI (Weight/height 2 ). Pts were separated according to LTI or FTI status into 4 groups: (1) Low LTI/LowFTI; (2) Low LTI/High FTI: (3) Normal LTI/Normal FTI and (4) Normal LTI/High FTI. We compared diffferent SP:BSA:Dubois (D) formula vs Levinsgton (L) formula); LBM-BCM vs LBM anthropometrically predicted (LBMpred) and V-BCM vs Watson (W) formula. We analized the behaviour of SP according BC groups using correlation coefficient (r), mean Erorr ( (BCM-pred/n) (E), root mean square error ( √ (R) 2 /n) (RMSE). Results: RMSE (BSA, LBM and V) were significantly higher in pts with High FTI (groups 2 and 4). R (± 2SD) between D and L formulas was -0,08 m 2 (+0,08/-0,24) and RMSE (BSA) correlated with BMI (r=0,85) and FTI (r=0,82). LBMpred highly overestimated LBM-BCM (-18kg (-2/-34) and related inversely with LTI (r=-0,87).W was less accurate to predict V in pts with Low LTI (groups 1 and 2) (r=-0,67 with LTI) (Table 1)   Table 1 Group (n)
ALL ( Conclusions: Changes in BC (expressed as Low LTI and/or high FTI) were related to increased Error prediction of SP formulas. L formula showed to be more sensitive to changes in BC than D formula. BCM seemed to be a powerful device for the calculation of LBM and V being robust in extremes cases of BC usually found in HD pts. Disclosure: Valtuille, Casos, Pinelli and Marelli work for FMC Argentina.
Transplantation -clinical research 2
OSu020 Relative and absolute counts of lymphocytes subsets (CD3+ T cells, CD3+CD4+ T helper, CD3+CD8+ T suppressor/cytotoxic, CD3-CD19+ B cells and CD3-CD16+ or CD3-CD56+ NK), activated T lymphocytes (CD3+HLA-DR+) and cytotoxic lymphocytes (CD8+CD57+) were assayed using two-color FACS analysis. Since CD57 surface expression correlates with the degree of cytotoxic activation, we have also distinguished between CD8+CD57 dim + and CD8+CD57 bright + as immunophenotypes associated with early and late activation respectively. In our centre, these quantitations are executed two times a week during transplant hospitalization and every six months after discharge. In case of hospitalization during the follow-up period the same assays are carried out twice a week. We collected all the data available for our patients and we compared the assessments closer to cancer diagnosis (±6 months) with the ones performed at least one year before cancer diagnosis. A switch to a belatacept-based regimen may be a safe option for patients maintained on tacrolimus or cyclosporine immunosuppression. Methods: This is a 12-month, randomized, open-label Phase II study of kidney transplant patients with stable renal function (MDRD GFR ≥35 mL/min and ≤75 mL/min) on a CNI-based regimen (either tacrolimus or cyclosporine). Patients 6 to 36 months post-transplantation were randomized to either belatacept 5 mg/kg (with CNI discontinuation) or continued treatment with their established CNI. All patients also continued background maintenance immunosuppression at stable doses, which could include mycophenolate, sirolimus, or azathioprine +/-corticosteroids. The primary outcome was the change in MDRD GFR from baseline to Month 12 following switch. Additional outcomes included the incidence and severity of acute rejection (AR) episodes and patient/graft survival at Month 12.
Results: 173 patients were randomized, and 171 were either switched to belatacept (n = 83) or remained on a CNI-based regimen (n = 88). At Month 12, the mean increase from baseline in MDRD GFR was 7.0 mL/min ± 11.99 in the belatacept group and was 2.1 mL/min ± 10.34 in the CNI group. Six patients in the belatacept group (7%) had an AR episode, vs none in the CNI group. All AR episodes occurred within the first 6 months, were Banff grade I or II, and none led to graft loss. Patient/graft survival was 100% in the belatacept group and was 99% in the CNI group at Month 12. One patient in the CNI group died due to myocardial infarction with a functioning graft. The overall safety profile was similar between groups. Four patients (2 in each group) had malignancies during the first 12 months. No cases of PTLD were reported. Conclusions: Switching to a belatacept-based regimen from a CNI-based regimen was safe, was associated with low rates of acute rejection, and resulted in improved renal function. Introduction and Aims: The pentraxin CRP is an acute phase protein and a marker for infection or AMI. It was suggested that an increase in its blood concentration is a prognostic marker for the risk of cardiac events. Evidences accumulated that CRP is responsible for an extension of the area of infarct in AMI. It can be assumed that immunological processes enhance the destruction of involved heart areas via the CRP-complement pathway in a notable part of the affected patients. CRP binds to lysophosphatidylcholine which is accessible in the membrane of necrotic and late apoptotic cells. Although this function is vitally important for the efficient clearance of materials from destroyed cells, extended tissue destruction caused by high and especially long lasting levels of CRP is contra productive, prolongs healing processes and enhances remodelling. Therefore, CRP removal from blood may be useful for acute treatment of patients with AMI. Methods: Our therapeutic approach is to lower the CRP concentration in blood after AMI by selective apheresis. We adapted a porcine infarction model (balloon catheter; n=2x5). A regenerative CRP-specific adsorbing system was created for the depletion of CRP from plasma. After cellplasma separation by filtering, the plasma was managed by a pump system (ADAsorb) with a specifically adapted software program. The first treatment started at about 16 hours after AMI, the second one after 44 hours. The treatment lasted for 2-3 hours. Two plasma volumes were treated. The CRP plasma concentration was reduced by 60-70%. We established a human like clinical care situation including magnetic resonance imaging. The observation period after infarction was 14 days. Infarct area -estimated by different methods -was the primary clinical endpoint. Results: We observed a significant decrease in infarct area (by MRI and histology of heart slices) in the verum (CRP apheresis) group but not in the control group (extracorporal plasma managing in a bypass system). In addition, we preserved nearly 60% of the ejection fraction in the verum group while decreased to about 45% in the control group (p=0,016).
Conclusions:
The results indicate an important, probably causative role of CRP for the progress and outcome of myocardial infarction. The data confirm our hypothesis about the pathological relevance of high levels of CRP in AMI and demonstrated the clinical benefit of CRP removal from blood.
OSu024 THE DINUCLEOTIDE UP4A ACTIVATES P2Y
RECEPTORS IN THE KIDNEY TO INDUCE VASOACTIVE RESPONSE
Markus Tölle, Mirjam Schuchardt, Tao Huang, Annette Wiedon, Lars Klöckl, Walter Zidek, Markus van der Giet. CC10 Neprologie and Transplantation, Charité -Campus Benjamin Franklin, Berlin, Germany Introduction and Aims: It has been shown that dinucleoside polyphosphates have great vasoconstrictive activities. An endothelium-derived dinucleoside polyphosphate with purine and pyrimidine moiety -uridine adenosine tetraphosphate (Up4A) has been identified as a potent vasoactive substance, mainly activating P2X1 receptors. But there were hints that further P2 receptors are involved in the vasoconstriction induced by Up4A. This study was to investigate the involvement of P2Y receptors in vasoactive properties of Up4A. Methods: In this study the model of isolated perfused rat kidney was used. Results: Under basal tone, Up4A caused a dose-dependent vasoconstriction (EC50 [log mol] = -8.3±0.1; vmax= 107±8 mmHg; n=6). α,β-meATP, a P2X1 desensitizer, significantly decrease responses to bolus application of Up4A, but did not completely abolish the effect. This remaining vasoconstriction could be nearby totally blocked by the unselective P2 receptor inhibitor suramin (100 μmol/L), whereas MRS2179 (10 μmol/L), a specific P2Y1 inhibitor, or the unselective inhibitor PPADS (10 μmol/L) had no significant effect. RB-2 (100 μmol/L) tended to reduce the remaining vasoconstriction without reaching significance. The continuous perfusion with Up4A led to a concentration-dependent increase of the perfusion pressure. Thereby, the perfusion pressure increase could be divided into two different parts: the first showed a fast response with desensitization and could be completely abolished by the parallel continuous perfusion with α,β-meATP, and significantly inhibited by suramin and PPADS, whereas MRS2179 and RB2 had no significant effect. The second part was a prolonged increase with a stable plateau which could only be significantly blocked by suramin and RB-2 whereas PPADS MRS2179 and P2X1/3 receptor desentization with α,β-meATP showed no significant inhibition. Conclusions: In this study we observed an Up4A-induced renal vasoconstriction, beside P2X1 receptor effect. The G-protein coupled receptor P2Y2 is additionally activated by Up4A. P2Y2 receptor activation has been shown to be also involved in proinflammatory signaling. Therefore Up4A might potentially also act as proinflammatory compound. , is most likely generated enzymatically. In the presence of mononuclear leukocytes, Ang II is converted to Ang A by decarboxylation of Asp1. Ang A has the same affinity to the AT1 receptor as Ang II, but a higher affinity to the AT2 receptor. In the isolated perfused rat kidney, Ang A revealed a smaller vasoconstrictive effect than Ang II, which was not modified in the presence of a AT2 receptor antagonist, suggesting a lower intrinsic activity at the AT1 receptor. Ang II and Ang A concentrations in plasma were determined by MALDI-TOF/TOF-MS, because conventional enzyme immunoassay for Ang II quantification did not distinguish between Ang II and Ang A. In healthy subjects, Ang A concentrations were less than 20% of the Ang II concentrations, but the ratio Ang A/Ang II was higher in end-stage renal failure patients. Conclusions: Ang A is a novel human strong vasoconstrictive angiotensinderived peptide, more likely generated by enzymatic transformation through mononuclear leukocyte-derived aspartate decarboxylase. Plasma Ang A concentration is increased in end-stage renal failure. Because of its stronger agonism at the AT2 receptor, Ang A may modulate the harmful effects of Ang II. 
Peritoneal dialysis
OSu026
HEAT STERILIZED PERITONEAL DIALYSIS FLUID IMPAIRS HSP EXPRESSION IN HUMAN PERITONEAL MESOTHELIAL CELLS
Introduction and Aims:
We have previously shown that exposure of mesothelial cells (MC) to peritoneal dialysis fluids (PDF) not only caused toxic injury during the acute exposure phase, but also induced cytoprotective heat shock proteins (HSP) during the subsequent recovery phase. This study was performed in order to evaluate the impact of the modality of PDF exposure on the heat shock response and cell survival. Methods: Omentum-derived human peritoneal MC underwent 3 modalities of exposure to heat-or filter-sterilized PDF: (A) pure PDF for 60 minutes followed by a recovery-period in pure culture medium for 24 hours (B) 1:1 mixture of PDF with culture medium for 24 hours or (C) pure PDF for 60 minutes followed by a recovery-period in a 1:1 mixture of PDF with culture medium for 24 hours. Cell survival was assessed by LDH-release into the supernatant, heat shock response was assessed by analysing HSP-72 in the cell lysates. Results: Only short term exposure of MC to pure PDF (Modality A) resulted in injury-dependent upregulation of HSP-72 with both heat-and filter sterilization. Continuous exposure to filter-sterilized PDF (Modalities B and C) resulted in preserved cellular viability -reflecting adequate HSP-72 induction. In contrast, the presence of heat-sterilized PDF during continuous/recovery exposure (Modalities B and C) resulted in significant downregulation of HSP-72 and severe cellular lethality.
Conclusions: Cellular survival was determined by the balance between toxicity induced injury and counteracting cellular responses. This study describes suppression of adequate HSP expression by heat-sterilized PDF as a novel cytotoxic property, likely mediated by GDPs. These findings might introduce a novel way of improving PDF biocompatibility by searching for tools and interventions to re-establish adequate counteracting cellular stress responses. Introduction and Aims: Survival analyses comparing renal transplantation (RT) and dialysis usually exclude patients who are not on RT waiting lists, but survival analyses on dialysis usually do not exclude patients for whom RT is planned. Keeping these patients may induce bias as they are both healthier and more likely to undergo RT before death during dialysis can occur. This competition between death and RT can lead to biased estimations for this patient subgroup. Methods: We first analyzed a cohort of 293 patients starting PD between 1992 and 2007 and treated with PD for more than six months in a single centre with a homogeneous RT strategy. We then verified our analysis on a cohort of 6 650 patients starting PD between 2002 and 2008 from the 'Registre de Dialyse Péritonéale de Langue Française'. We estimated cumulative incidences for death, RT and transfer to hemodialysis according to whether RT was planned or not. We explored risk factors for death, RT and transfer to hemodialysis using Gray's test or the Cox test. Results: RT was planned for 114 (39%) patients, none of whom died. At 6 years of PD, the estimated probability of RT for these patients was 74% and, of transfer to hemodialysis, 26%.
OSu027 SELECTION BIAS DUE TO RENAL TRANSPLANTATION IN PERITONEAL-DIALYSIS SURVIVAL ANALYSIS
They were younger and had fewer comorbidities. In the total population, older age, diabetes, low albumin, low residual renal function, and CRP were significant risk factors for death and significant protective factors for RT. In univariate Cox models, interaction terms with RT were significant (p<0.05) for all significant risk factors for death. Therefore, the death hazard ratio could not be estimated independently of RT. The national registry data confirmed these results: of 2205 patients with RT planned (33%), only 100 (4.5%) died, 1075 (48.8%) underwent RT, and 598 (27.1%) were transferred to hemodialysis. Age and diabetes were inversely related to death and RT. Conclusions: Patients for whom RT is planned represent more than a quarter of PD patients. These patients are much more likely to undergo renal transplantation than to die on PD. This competition between death and RT for these patients means that relative risks for death cannot be estimated independently of RT in the total population. This selection bias should be taken into account in PD survival analyses. This consideration might extend to hemodialysis studies. vs. 12mm (11-13); P= 0,005] were significantly higher in the group with FO. After multivariate adjustment analysis including age, comorbidity, lean tissue and proBNP only albumin remained significantly related with FO (OR=0,01, CI 0,01-0,8; P= 0,03). Conclusions: Fluid overload assessed by BCM was present in 18% of our prevalent PD population. Age, higher comorbidity, lower albumin levels and lower lean tissue mass were associated with FO in our cross-sectional analysis, but not traditional cardiovascular risk factors, inflammation, fluid removal, peritoneal transport or PD modality. Low albumin is highlighted as a marker of volume expansion in this study. Hypertension was not more prevalent in patients with FO, but humoral (proBNP) and structural markers of cardiac overload were clearly higher in overhydrated patients. Introduction and Aims: Peritoneal dialysis is limited by toxicity due to GDPs, generated during heat sterilization of PD-fluids. Glyoxalase I plays a critical role in the prevention of glycation reactions and may be protective in PD. Methods: We compared the effects of PDFs with different amounts of GDPs on morphological changes of the peritoneal membrane examining 48 wild type (WT) and 48 Glyoxalase I -deficient mice. PDFs (1 ml) were instilled twice daily over a period of 12 weeks. Groups with 12 animals each received either no manipulation (sham), sham instillation (sham i.p.), or instillation of different GDP-containing PDFs. Results: A GDP-dependent increase of peritoneal AGE formation occurred in WT and glyoxalase I deficient mice. Compared to WT mice Glyoxalase I-deficient mice showed a marked increase of markers of inflammation (i.e., CD3+ T-cells, IL6 expression), as well as neoangiogenesis (i.e., VEGF expression) and fibrosis (i.e., expression of TGF-β1) after a long-term exposure to GDP-containing PDFs.
OSu028 PERITONEAL DIALYSIS DOSE IN EUROPE: ASSESSMENT OF PRACTICE PATTERNS IN 6 REGISTRIES
OSu030 PRONOUNCED PERITONEAL DAMAGE IN GLYOXALASE I-DEFICIENT MICE
Conclusions:
Glyoxalase I plays a pivotal role in GDP associated peritoneal toxicity. The performance of pNGAL as a diagnostic test for AKI showed a specificity between 77% to 82%, and sensitivity between 61% to 68%. Conclusions: These results indicated that pNGAL is a good biomarker of AKI with better diagnostic power when patients are discriminated by grade of severity. The relationship between pNGAL and AKI varies with the preexisting renal disease. pNGAL attained a better discriminatory performance in AKI patients with previous CKD. Introduction and Aims: Acute kidney injury (AKI) is a common condition in intensive care unit (ICU) patients and associated with high mortality. In order to prevent its progression and to improve its outcome, early and accurate detection of AKI is crucial. In pilot studies kidney injury molecule 1 (KIM-1) was proposed as a promising early marker for AKI. However, later studies could not confirm these findings making it necessary to search for other, more predictive markers. Methods: We used capillary electrophoresis mass spectrometry to identify urinary peptide markers predictive for AKI in urine samples obtained from indwelling bladder catheters of ICU patients who later developed AKI (maximum 5 days prior AKI) defined by a serum creatinine increase ≥ 50% in ≤ 48 hours or maintained normal kidney function. The statistically most significant markers were combined to a support vector machine classification model and validated on a blinded set of ICU patient samples. Classification accuracy of the proteomic model in this patient collective was compared to that based on urinary KIM-1 levels. Results: A combination of 20 peptides allowed classification of a blinded test set of ICU patient samples (n=20, 9 case and 11 controls) with 89% sensitivity and 82% specificity. In order to evaluate general applicability, the urinary proteomic model was further applied to the classification of single-void urine samples from hematopoietic stem cell transplanted patients of which 13 developed AKI after transplantation and 18 did not. AUC in this validation set was 0.90 with sensitivity and specificity values of 94 and 82%, respectively. The 20 polypeptides were identified by amino acid sequencing as degradation products of 6 proteins. Fragments of albumin, α-1-antitrypsin and β-2-microglobulin were up-regulated, fibrinogen α chain, collagen 1 α(I) and collagen 1 α(III) were down-regulated in AKI. Compared to the proteomic model, ROC curve analysis revealed poorer classification accuracy of KIM-1 with the respective AUC values being outside the statistical significant range (0.67 for the ICU and 0.57 for the HSCT validation set).
Acute kidney injury -clinical research
OSu032 DIAGNOSTIC MARKER PATTERN OF SEQUENCED URINARY PEPTIDES FOR EARLY AND ACCURATE DETECTION OF ACUTE KIDNEY INJURY
Jochen
Conclusions:
In contrast to KIM-1, the proteomic marker pattern allowed accurate detection of AKI as early as 5 days in advance of serum creatinine irrespective of the patient population in whom AKI occurred. Introduction and Aims: Extracorporeal membrane oxygenation (ECMO) enables an efficient oxygenation and elimination of carbon dioxid independent of cardiac and pulmonary function and is increasingly used in the intensive care unit setting. Patients undergoing ECMO therapy do also frequently suffer from acute kidney injury. So far little is unknown how the combination of these two conditions affects survival of critically ill patients. Methods: At a tertiary care centre we retrospectively evaluated all patients undergoing ECMO treatment between January 2005 and June 2009. Data from all 122 patients (67M), mean age 45 years were obtained by chart review. Follow up data up to 98 days were obtained. Results: Sixty-nine (56%) of 122 patients undergoing ECMO therapy was also treated by renal replacement therapy (RRT). Nineteen patients (15%) were already dialysis dependent before initiation of ECMO treatment. The overall 98 day survival of the patients was 25.4%. While patients without RRT showed a mean 98 day survival of 48% the survival of patients with RRT was only 7%.
OSu033 EFFECT OF ACUTE KIDNEY INJURY REQUIRING RENAL REPLACEMENT THERAPY (RRT) ON SURVIVAL OF 122 PATIENTS UNDERGOING EXTRACORPOREAL MEMBRANE OXYGENATION (ECMO)
Conclusions:
The concomitant necessity of RRT in patients undergoing ECMO treatment increases mortality in ICU patients dramatically. Future studies have to clarify whether it is possible to identify patients that show a long term benefit from the combination of these two extracorporeal treatment methods.
Introduction and Aims:
Community-acquired pneumonia (CAP) is common and associated with a considerable risk of acute kidney injury (AKI) and death. Early and accurate risk stratification is an unmet clinical need. The ability of admission NT-proBNP levels to predict AKI and death in patients is presently unknown. Methods: We prospectively enrolled 422 patients presenting to the Emergency Department with CAP (mean age 75, female 167). NTproBNP was measured in a blinded fashion at presentation. Acute kidney injury was defined -according to AKIN guidelines-as an increase of creatinine over 0.3mg/dl that persisted for at least 24 hours. The potential of admission NT-proBNP levels to predict AKI and death was assessed as the endpoint. The median follow up was 948 days . Results: NTproBNP on admission was significantly higher in patients who developed a sepsis related acute kidney injury 48 hours after the presentation (1255 [1937-30828] vs 703 [185-3506] pg/ml, P<0.001). Admission NTproBNP levels were strong predictors of AKI: in a +ROC curve analysis for the prognostic accuracy of NTproBNP, the AUC was 0.79 (SD 0.062, 95% CI 0.670-0.913), as shown in Fig. 1 . In univariate regression analysis admission NTproBNP levels significantly predicted the development of in-hospital AKI (OR 1.007; 95%CI 1.003-1.010; P<0.001 for increase of 100 pg/ml). Similarly, admission NTproBNP levels were significantly higher in shortand long-term non-survivors compared to survivors (NTproBNP median 4052 (1273-10504) vs 944 (231-3948) pg/ml, P<0.001; NTproBNP median 2707 (705-9361) vs 528 (123-1932), P <0.001); The AUCs for the prediction of short-term mortality and long-term mortality were 0.703 (SD 0.041, 95% CI 0.623-0.0783) and 0.730 (SD 0.025, 95%CI 0.681-0.781), respectively. The potential of NTproBNP to predict short-term mortality was comparable to the currently used PSI score (AUC 0.762, SD 0.033, 95% CI 0.697-0.827, P comparison 0.153). In Cox regression analyses admission NTproBNP levels significantly predicted short and long term mortality (HR 1.002; 95%CI 1.001-1.003; P<0.001 for increase of 100 pg/ml; HR 1.002, 95%CI 1.002-1.003; P<0.001 for increase of 100 pg/ml respectively). The cumulative long-term survival stratified according to the calculated cut-off is in Fig. 2 . Conclusions: In patients presenting with CAP admission NTproBNP predicts the development of AKI as well as short and long-term mortality. 
OSu035 PHARMACOKINETICS OF DAPTOMYCIN IN CRITICALLY ILL PATIENTS WITH RENAL FAILURE AND UNDERGOING CONTINUOUS VENO-VENOUS HEMODIALYSIS (CVVHD)
Introduction and Aims:
Daptomycin is a novel antibiotic with potent bactericidal activity against Gram-positive pathogens and primarily renal elimination. Methods: In an investigator-initiated, open-labelled study, the plasma pharmacokinetics of Daptomycin were determined after a single intravenous loading dose of 8 mg/kg total body weight (TBW) and following multiple doses of 4 mg/kg TBW at steady-state conditions every 48 h in eight critically ill, dialysis-dependent patients scheduled to undergo continuous veno-venous hemodialysis (CVVHD). CVVHD involved a targeted dialysate turnover of 2 L/hour, a high flux filter and citrate for anticoagulation. Four healthy subjects received a single dose of 4 mg/kg TBW of Daptomycin over 24 h and were used as controls. Daptomycin concentrations were determined by high-performance liquid chromatography. Results: The following table summarizes the pharmacokinetic results. The dialysis doses achieved were 30.1±2.7 ml/kg TBW/h (Single dose) and 31.6±4.0 (Steady state), with filter running times of 98% and 92% of the 48 h interval, respectively. Approximately 40% of the Daptomycin dose administered was removed by CVVHD over a period of 48 hrs. Mean plasma half-lives (t ½ β) of Daptomycin in CVVHD patients were 2-3 times longer as compared with healthy controls. However, this marked prolongation of the half-life was unable to provide a sufficient drug expose in the second part of the dosing interval (AUC 24-48h ) in the critical ill CVVHD patients. Conclusions: Based on pharmacokinetic-pharmacodynamic calculations, the currently recommended dosing regimen of 4 mg/kg TBW of Daptomycin administered to CVVHD patients every 48 h is inappropriate to achieve effective antimicrobial concentrations of Daptomycin in plasma over the entire dosing interval. Doses between 3-4 mg/kg TBW administered intravenously every 24 hrs are necessary in CVVHD patients to assure that plasma Daptomycin levels are comparably high to subjects with normal renal function and to avoid underdosing. Disclosure: This study was supported by a grant from Novartis Germany.
Cardiovascular diseases 2
OSu036 Introduction and Aims: Calcific uremic arteriolopathy (CUA, calciphylaxis) is a rare and devastating condition associated with high morbidity and mortality mainly occurring in dialysis patients. CUA is characterised by painful, ischemic, partly necrotic skin ulcerations. Pathomorphologically, media calcification of cutaneous arterioles is the hallmark of the disease. Little is known about the exact incidence and risk factors are only partially established. The aim of the International Collaborative Calciphylaxis network (ICCN) is to collect data concerning incidence and risk factors for CUA. Moreover, we try to gain overview about current treatment strategies and link them to the clinical course. Serum analyses will particularly aim at the assessment of the role of inflammation as well as calcification inhibitors and inducers. This data collection is intended to be the basis for future prospective treatment trials. Methods: The Germany-based ICCN established an international internetbased registry in 11/2006 (www.calciphylaxie-register.ukaachen.de) to allow online notification for all cases of established or suspected CUA. A comprehensive data base including various parameters concerning patient characteristics, laboratory data, clinical background and presentation as well as therapeutic strategies was established. Follow-up of the patients is planned by regular queries of long-term outcome. The diagnosis of CUA is made on clinical and/or histological grounds by the referring physician. Results: Within three years altogether 81 patients with CUA have been documented: 51 female (63%); 69 (85%) dialysis patients, 7 (9%) CKD or post-transplant pts; mean age 63 (31-88) years. Laboratory data from dialysis patients: Mean serum total calcium: 2,2±0,2 mmol/L (n=2 above K/DOQI target range); mean phosphorus: 2,17 mmol/L (54% above K/DOQI, 17% > 2,5 mmol/L). PTH levels varied broadly between undetectably low and > 1300 pg/ml, median 467 pg/mL. 67% of all patients had CRP levels > 10 mg/l. Oral anticoagulation was common (48% of all patients). Cutaneous lesions were localized in 87% at the lower extremities or gluteal region. Among the most frequently recorded therapeutic procedures were: surgical necrosectomy, intensifying dialysis modality, i.v. sodium-thiosulfat application, lowering calcium burden by reducing dialysate calcium and/or reducing oral calcium-containing phosphate-binders, application of calcimimetics, systemic antibiotics, and stopping oral anticoagulation. Hyperbaric oxygen therapy was not applied. Conclusions: As previously suspected, CUA seems to be associated with inflammation and oral anticoagulation. At the time of diagnosis, serum calcium is mostly normal, while phosphorus serum levels are elevated in most cases, according to CKD stage 5D. PTH levels vary substantially. Decisions on therapeutic strategies also vary significantly among centers. The present internet based ICCN registry is a valuable tool to collect data upon CUA cases and may become a basis for prospective systematic evaluations of treatment modalities in the near future. Disclosure: Study support by AMGEN grant.
Introduction and Aims:
End-stage renal disease (ESRD) patients experience a very high incidence of sudden cardiac death (SCD). This study aimed to evaluate the role of echocardiography and additional value of serum biomarkers in predicting SCD in ESRD patients. Methods: We performed a 5-year prospective follow-up study in 230 ESRD patients (mean age: 56±11years; 51% male gender). 2D-echocardiography was performed at baseline together with measurement of a panel of serum biomarkers including C-reactive protein (CRP), interleukin-6 (IL-6), myeloperoxidase (MPO), fetuin-A, cardiac troponin T and N-terminal probrain natriuretic peptide (NT-pro-BNP). These parameters were studied in relation to the outcome 'SCD'. Results: During the 5-year follow-up, a total of 115 death have occurred of which 24% were due to SCD. In the multivariable Cox regression analysis considering clinical, biochemical, dialysis and echocardiographic parameters, left ventricular systolic dysfunction emerged as the most significant, independent predictor of SCD (P=0.0012), followed by a high systolic blood pressure (P=0.0057) and a low diastolic blood pressure (P=0.0044). An ejection fraction cutoff ≤ 48% is associated with a specificity of 78.6% and a sensitivity of 57.7% in predicting SCD. In the biomarkerbased multivariable Cox regression analysis, a high systolic (P=0.023) and a low diastolic blood pressure (P=0.0023) retain independent significance for SCD. NT-pro-BNP displays independent significant association with SCD (P=0.0044) and is more significantly associated with SCD than cardiac troponin T (P=0.061). Other serum biomarkers including CRP, IL-6, fetuin-A and MPO showed no independent predictive value for SCD. In the combined echocardiography and biomarker-based multivariable Cox regression model, LV systolic dysfunction (P=0.004), a high systolic (P=0.0031) and a low diastolic blood pressure (P=0.0033) retained independent significance in predicting SCD. NT-pro-BNP loses significance to left ventricular ejection fraction while cardiac troponin T retains significant association with SCD (P=0.031) independent of echocardiographic parameters. Conclusions: In conclusion, systolic dysfunction is the most significant predictor of SCD in ESRD patients followed by a high systolic and a low diastolic blood pressure. Our data suggests additional value in measuring cardiac troponin T for SCD risk stratification in ESRD patients. NT-pro-BNP may be used in place of echocardiography to identify patients at risk of SCD but had no added value over echocardiography in predicting SCD. Results: Among 235 randomized subjects who had CAC scores at baseline and week 52 and had not taken prohibited medications, calcification was present at baseline at the aortic valve in 108 (46%) and at the mitral valve in 118 (50%). In those with evidence of valvular calcification, median (P10, P90) Agatston scores at the aortic valve increased 52% (-86, 200) in the flexible vitamin D group and 6% (-100, 105) in the cinacalcet plus low-dose vitamin D group (p=0.014), whereas the corresponding increases in volume scores were 35% (-84, 184) and 9% (-100, 88), respectively (p=0.035). Similarly, mitral valve Agatston scores increased 54% (-55, 823) in the flexible vitamin D group and 12% (-39, 443) Little is known about the expression and functions of connexins in the kidney. We have therefore determined the expression patterns of all connexins in the developing and in the adult mouse kidney. Methods: The expression of all connexin members was investigated in kidney tissue of different developmental stages by RT-PCR and immunohistochemistry. Results: We found expression of the connexins Cx26, Cx30, Cx32, Cx37, Cx40, Cx43, Cx45 and Cx46 in characteristic time-and site-specific patterns. Cx37, Cx40, Cx43, Cx45 and Cx46 were restricted to the glomerularvascular system. Among all connexins found in the kidney the highest expression levels were measured for Cx26 and Cx32, which colocalized with megalin-expressing proximal tubular cells. The developmental expression patterns of Cx26 and Cx32 were similar. They were first detected at embryonic day 16 in a small subset of tubular structures colocalizing with megalin. Around birth, apparently all proximal tubules expressed Cx26 and Cx32. Conclusions: Since apart from Cx26 and Cx32 no other connexin proteins could be found in the proximal tubules, we infer that these two proteins form gap junctions between proximal tubular cells, which have been demonstrated by electron microscopy before. Since the functional meaning of gap junctions in the proximal tubule is unknown, our data suggest that the use of genetically engineered mice with defects in Cx26 and Cx32 may assess the role of gap junctions in the development and function of the proximal tubule. also in other organs such as pancreas, thyroid, nervous central system and muscles. Untreated, cystinosis is a devastating disease. However, adequate cysteamine treatment may delay organ dysfunctions. We studied the outcome of the French adult cohort and the impact of a long-term oral cysteamine administration. Methods: This is a retrospective study of 86 adult patients diagnosed with infantile nephropathic cystinosis between 1961 and 1995. Clinical characteristics and treatment were collected, including clinical outcome and biochemical data. Results: At last follow-up, mean age of patients was 26.7±7.1 years (range: 15.1 to 50.1). Genetic screening showed that 38% of the patients were homozygous for the European 57kb deletion of the CTNS gene and 25% compound heterozygous for that deletion and another mutation. Cysteamine therapy was administered to 82% of the patients and started at a mean age of 9.9±10.3 years (range: 0.9 to 38.6). The mean cysteamine treatment duration was 13.9±8.4 years (range: 0.0 to 27.8). 91% of patients reached end stage renal disease (ESRD) at a mean age of 11.1±4.0 years; 72% had hypothyroidism at a mean age of 13.4±6.1 years, 55% had diabetes at a mean age of 17.1±7.2 years, and 37% had neuromuscular disorder at a mean age of 23.3±6.3 years by the end of the study. However, life expectancy significantly increased in cysteamine treated patients in comparison to non treated ones (29.4±7.8 and 21.6±4.6 years respectively, p=0.04). KaplanMeier survival curves showed that more than 5 years of cysteamine treatment significantly delayed the occurrence of ESRD, hypothyroidism, diabetes and neuromuscular disorder. ESRD negatively correlated with the age at start of the treatment (r=-0.3, p=0.01). An adequate compliance and a current leukocyte cystine level under 3 nmol half-cystine/mg protein delayed ESRD (p<0.001). Furthermore, starting cysteamine before the age of 5 delayed ESRD, hypothyroidism, diabetes and neuromuscular defects (p=0.001). The first complication to occur was ESRD in 76% of cases, hypothyroidism in 21%, diabetes in 2%, and neuromuscular disorder in 1%. Conclusions: Cysteamine treatment increases life expectancy of cystinotic patients. This large series shows that a duration of treatment longer than 5 years delay complications onset (ESRD, hypothyroidism, diabetes, neuromuscular disorder), especially if the treatment is started before 5 years of age. Adult nephrologists must then insist on the adherence of treatment throughout the life.
OSu039 THE EFFECTS OF CINACALCET PLUS LOW-DOSE VITAMIN D ON CARDIAC VALVE CALCIFICATION IN HEMODIALYSIS PATIENTS WITH SECONDARY HYPERPARATHYROIDISM
OSu046
MULTIPLE NEW GENETIC LOCI ASSOCIATED WITH KIDNEY FUNCTION AND CHRONIC KIDNEY DISEASE: THE CKDGen CONSORTIUM
Introduction and Aims:
We recently identified Thrombospondin-2 (TSP-2) as a regulator of matrix remodelling and inflammation in experimental kidney disease by using TSP-2 null mice or TSP-2 overexpression in anti-Thy1 nephritic rats. In this study we investigated if long term TSP-2 overexpression is also capable to ameliorate the progression of a chronic kidney disease via anti-fibrotic and anti-inflammatory effects using the chronic allograft nephropathy (CAN) F344-Lewis model in the rat. Methods: Two weeks after renal transpantation rats were transfected with either a TSP-2 overexpressing plasmid (n=8) or a luciferase-expressing plasmid as control (n=8) using transfection in the thigh muscles by electroporation. Rats were monitored for renal function and histological changes in the graft using immunohistochemistry 30 weeks after transplantation. Results: Surprisingly, only in the TSP-2 treated group 2 rats died before the end of the experiment. Renal function, as measured by proteinuria, creatinine clearance, serum creatinine and serum urea tended to be worse in the TSP-2 group compared to the luciferase-treated controls. In addition, glomerular sclerosis (score: 1,3±0,3 vs. 1,9±0,6) and tubular interstitial injury (score: 1,2±0,3 vs. 2,2±0,7) was significantly increased in the TSP-2 treated kidneys. Podocyte injury, as assessed by desmin staining, was also significantly higher in the TSP-2 treated group compared the luciferase transfected controls. Long term TSP-2 therapy impaired repair of renal endothelium, as demonstrated by significant higher glomerular (score: 2,0±0,5 vs. 2,5±0,4) and peritubular (score: 49,6±4,3 vs. 62,4±4,5) endothelial rarefaction in the transplanted kidneys from TSP-2 treated rats compared to luciferase-treated controls. Furthermore, number of lymphatic vessel cross-sections, as assessed by podoplanin staining, was significantly reduced in TSP-2 treated rats compared to luciferase-treated controls.In contrast, renal inflammation was significantly ameliorated in the TSP-2 treated group, as assessed by counting glomerular and tubulointerstitial macrophages, CD8 positive T-cells and CD45R positive B-cells reaching reduction rates from 31% up to 68%. Conclusions: Despite its anti-inflammatory effects, TSP-2 long-term gene therapy did not ameliorate but rather worsened experimental CAN in the rat most likely via increased capillary and lymphatic vessel rarefaction.
Prominent vascular injury is a hallmark of reperfusion injury after extended cold preservation times. We hypothesized that inhibition of signal transduction mediated by protein kinase-C may be protective and evaluated the effect of an inhibitor of conventional isoforms of protein kinase-C (AEB071) on rat renal transplants with prolonged cold preservation and compared it to a derivate of mycophenolic acid -EC-MPS, and vehicle treatment. Methods: Donor kidneys were cold-stored in UW for 24 h prior to transplantation into bilaterally nephrectomized syngeneic recipients (n = 6/group) which received 30 mg/kg/bid AEB071, 20 mg/kg/day EC-MPS or vehicle via oral gavage with first application at 2 hours before transplantation and subsequent doses given at 12 or 24 h intervals. Serum creatinine was measured 24 h posttransplant. Renal tissue was examined histologically, stained for apoptosis, inflammatory cell infiltrates, and studied for MCP-1, iNOS, and eNOS gene expression. Protein extracts served for measurement of stress-kinase Erk phosphorylation. Results: Serum creatinine measurement 24 h after transplantation revealed that only AEB071 group enhanced immediate transplant function. Although both EC-MPS and AEB071 inhibited intragraft expression of MCP-1 and iNOS and subsequent ED1+ monocytes/macrophages infiltration, only AEB induced increase in eNOS expression and abolished phosphorylation of Erk. Tubular apoptosis was significantly reduced after AEB071 treatment compared to both control groups. Conclusions: Unlike other immunosuppressants, AEB071 confers tubular epithelial and endothelial protection while in parallel reducing intragraft inflammation in the presence of severe preservation injury. Given its strong antiinflammatory and antiapoptotic properties, AEB may be a suitable immunosuppressant in the setting of delayed graft function. Disclosure: This work was supported by a grant from Novartis Pharma AG.
There have been few data comparing adverse events (AE) of IV iron products since 2002. There has been much experience with products that were relativley new to US market then (ferric gluconate [FG] and iron sucrose [IS] ). There has not been a comparison of AE between Europe (EU) and N. America (NA). Methods: All IV iron-related AE reported to the WHO from EU (Au, Cz, Den, Est, Fin, Fra, Ger, Ire, Ita, Nor, Pol, Spa, Swe, Swi, Tur, UK) or NA (US, Can) between 1Q03 and 2Q09 were obtained from the Uppsala Monitoring Center, Swe. AE were categorized by MedDRA and WHO-ART definitions. Iron may have been used in both CKD and non-CKD patients. Sales data per product and country were purchased from IMS Health and standardized to 100 mg dose equivalents (DEq) of iron. Total, anaphylaxis (AX) and anaphylactoid (AT) AE rates were calculated as # AE/# doses and compared for EU and NA. AT were defined as before (Bailie et al, NDT 2005; 20:1443-9) . Data were rejected if sales data were unreliable, a product had been in use for <2 years, obvious under-reporting from a country, reports were duplicated or unclear. Results: Annual sales (millions of 100 mg iron DEq) increased from 1Q03 to 2Q09 in EU for FG (1.4 to 1.6), iron polymaltose (IP, analysed for Tur only) (0.38 to 0.59), IS (0.65 to 1.9) and dextran (ID) (0.02 to 0.15, low MW only since 05). In NA sales increased for IS (1.1 to 2.8), remained unchanged for FG (1.0 to 0.97) and decreased ID (0.33 to 0.26). In EU and NA, total, AX and AT rates were many-fold higher for ID than other iron products. All rates increased over time, since the rates for 08-09 were higher than 03-09. NA had higher total, AX and AT rates than EU for FG but lower for IS. All rates were lowest in NA for IS. Total rates for NA+EU were similar for FG and IS. EU reports for IS did not specify originator or similars. Conclusions: IS had greatest increases in use in EU and NA. More AE in NA for ID may reflect more use of high MW in NA. Low rates for IP are due to under-reporting. There is a general increase in total, AX and AT reporting rates over time. Reasons are unclear but may be due to use of IV iron by non-nephrologists in other disease states, use of unapproved dosing methods or high doses, changes in reporting requirements, introduction of IS similars, mandatory substitution or tendering. Future influences of bundling and new products are unknown. Disclosure: GRB has received grants and speaking fees from pharmaceutical companies that market parenteral iron preparations in various countries. No sponsorship was provided for the current work. IMS and WHO data were purchased by Vifor Pharma Inc.
with higher mortality rates. The aim of this study was to investigate the association between systolic and diastolic blood pressure and time to RRT and rate of decline in renal function in pre-dialysis patients, to assess whether reverse epidemiology is already present in pre-dialysis patients. Methods: In the retrospective PREPARE cohort 547 incident pre-dialysis patients were included when referred to pre-dialysis outpatient clinics between 1999 and 2001. The clinical status of the patients was followed through medical charts until start of RRT or mortality. Rate of decline in renal function was calculated with available eGFR measurements, calculated by the MDRD formula. All analyses were performed with 1 year follow-up after inclusion. Linear regression was used to assess the association between blood pressure and decline in renal function, and Cox regression for time to RRT. Results: Every 10 mmHg increase in systolic or diastolic blood pressure resulted in a more rapid rate of decline, with a sex and age adjusted decline of 0.04 (0.02-0.07) and 0.05 (0.00-0.10) ml/min/month/1.73 m 2 respectively. Sex and age adjusted rate of decline in patients with systolic blood pressure <120 mmHg or ≥180 mmHg was 0.24 (-0.07-0.54) lower and 0.26 (0.03-0.50) ml/min/month/1.73 m 2 higher respectively, compared with patients between 120-139 mmHg (mean decline of 0.37 ml/min/month/1.73 m 2 ). Further adjustment did not change these results. The risk for starting RRT increased with every 10 mmHg increase in systolic or diastolic blood pressure, with a sex and age adjusted HR of 1.10 (1.05-1.15) and 1.16 (1.05-1.27) respectively. The HR for starting RRT was 0.89 (0.48-1.67) for systolic blood pressure <120 mmHg and 2.30 (1.52-3.47) for ≥180 mmHg, with 120-139 mmHg used as reference. Further adjustment did not change these results. Conclusions: Reverse epidemiology was not present in our pre-dialysis cohort, where only an increase in systolic or diastolic blood pressure is associated with a more rapid rate of decline in renal function and an earlier start of RRT. Patients with low blood pressure had less renal decline and a later start of RRT. Therefore, strict treatment of pre-dialysis patients with a low blood target goal, especially for systolic blood pressure, could be beneficial to postpone RRT and will lead to lower mortality rates. Disclosure: This study was funded by an unrestricted grant from AMGEN BV (The Netherlands and Switzerland). The sponsor of the study was not involved in study design, collection of data, statistical analysis, interpretation of data and writing of the abstract. Introduction and Aims: Alternative splicing is important to control gene expression in eukaryotes. It produces diversity of proteins from one initial genomic sequence. Renal failure is associated with various complications and particular cardiovascular complications and infectious disease. The molecular mechanisms involved in uremic complications are poorly understood. Alternative splicing machinery could be altered by uremic toxins. New isoforms produce could be responsive of some complications. We used PKD1 gene as a proof of this new concept. Methods: RNA from hemodialysed patients, uremic patients (eGFR between 15 ml/mn and 60 ml/mn) and controls was extracted from PBMCs using trizol. The RNA was reverse transcribed in cDNA. Specific amplification was performed using primers recognizing only PKD1 and not the partial homologs. For cell culture, primary PBMCs were grown for 48 hours in different media (uremic and non uremic). After 48 hours, the cells are harvested and RNA was immediatly extracted and reverse transcribed to identify the alternative splicing of PKD1. Results: We reported 11 new alternative splicing events in PKD1 gene. The 30 exon is preferentially spliced in uremic patients. We conduct a pilot study comparing hemodialyzed patients for more than 10 years and control patients without uremia. The splicing is present in 98% of hemodialyzed cohort (n=24) and 5% of control cohort with normal GFR (n=20) (chi square=43, p<0.001). We conduct a confirmation study to explore the effect of dialysis. We searched the alternative splicing in three cohorts of patients, 1) hemodialyzed patients (n=38), 2) patients with eGFR < 60ml/mn (n=29) and 3) patients with GFR > 60ml/mn (n=31). Age, sex ratio and diabetes frequencies are equivalent in the groups. We identified the alternative splincing in 100% of the hemodialyzed patients, 75% of non hemodialyzed patients and 30% of non uremic patients. In multivariate analysis, the only factor associated with the presence of the alternative splicng of exon 30 of PKD1 is uremic status (OR=0.03 (CI95%= 0.002-0.238)). To confirm the association between uremia and splicing event of exon 30 we realized short term culture of leukocytes incubated with uremic media or normal media. Alternative splicing disappeared in non uremic conditions and is re-induced in uremic media.
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Conclusions:
We proposed uremia as a new modulator of alternative splicing machinery. Alternative splicing of genes could explains abnormal functions of various pathways in uremia. The deregulation of spliceosome in uremia is a promising way of research to understand the molecular basis of the complication of chronic renal failure.
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